Business
Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22
Platform Now Available with Introductory, Academic, & Commercial Subscription Tiers Live Debut at Nasdaq MarketSite, New York City — April 16, 2026,
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nPlatform Now Available with Introductory, Academic, & Commercial Subscription Tiers\n\n\n\nLive Debut at Nasdaq MarketSite, New York City — April 16, 2026, 12:00–2:00 PM Eastern\n\n\n\nPublic Demonstrations at AACR 2026, San Diego — Booth 5054, April 17–22\n\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (Nasdaq: LTRN) (“Lantern” or the “Company”), an AI-driven clinical-stage precision oncology company, today announced that withZeta.ai — the world’s first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, biomedical research, molecular design and clinical trial development — is now commercially live and actively onboarding subscribers. Subscriptions are available immediately at withzeta.ai, spanning introductory, academic, and commercial tiers, and represent a new, non-dilutive revenue stream for Lantern Pharma shareholders. The platform’s commercial debut will be showcased through two landmark events: a private investor briefing at Nasdaq MarketSite in New York City on April 16, 2026, and public demonstrations at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego at Booth 5054 during April 17–22.\n\n\nwithZeta.ai is the next generation of the AI platform technologies from RADR®, an oncology focused experimental biology and molecular analysis platform Lantern Pharma has built for its own cancer programs — and is now making available to the broader drug discovery and research communities. For rare cancer patients who cannot afford to wait decades for new therapies, it is an AI for good — one with a genuine and immediate opportunity to change the pace, cost, productivity and precision of drug discovery.\n\n\nThe Nasdaq MarketSite Debut — April 16, 2026\n\n\nOn Thursday, April 16, 2026 from 12:00 PM to 2:00 PM Eastern, Lantern Pharma will host an exclusive live demonstration of withZeta.ai at Nasdaq MarketSite in New York City — one of the world’s most recognized venues for presenting innovation to the financial and biotech investment community. The event will bring together 25 of the biotech industry’s leading investors, analysts, and media professionals for a first-hand experience of the platform in action, including live multi-agentic research workflows, real-time multi-database querying, development of a molecule for a rare cancer indicat...